Cases were managed with topical therapy, as previously described [6] . In 19 cases (65.5%), conjunctivitis was recovered/resolved or recovering/resolving by the end of week 16. Nine cases (31%) were not recovered/resolved and one case (3.4%) was recovered/resolved with sequelae.
Dupilumab treatment was discontinued for 1 patient due to bilateral conjunctivitis and cicatricial ectropion (Table) .
Factors significantly associated with dupilumab-associated conjunctivitis at univariable analysis (detailed in the Supplementary Table) included family history of allergic conjunctivitis (HR: 2.77, 95% CI 1.05 to 7.29), history of conjunctivitis (HR: 21.31, 95% CI 5.03 to 90.26), presence of other atopic conditions (HR: 2.51, 95% CI 1.21 to 5.24), SCORAD score (>76.6 compared to <76.6; HR: 2.29, 95% CI 1.04 to 5.05), baseline IgE levels (>3637 compared to <=100; HR: 3.15, 95% CI 1.2 to 8.26) and baseline blood eosinophil counts (>350 compared to <=350; HR: 3.99, 95% CI 1.71 to 9.29). The stepwise selection procedure to evaluate multivariable regression remove all predictors except history of conjunctivitis, obviously HR and 95% CI were the same, R-square was 0.39 and C-index resulted 0.53.
Recently, dupilumab-associated conjunctivitis has been reported in up to 50% of AD patients undergoing treatment [5] and predictors of its incidence are not well known. Over a 16week observational period, the current study reports a prospectively registered incidence of conjunctivitis in 40.3% of patients without conjunctivitis at baseline. Cases were mostly mild-ormoderate (90%) and were resolved/resolving with patients continuing dupilumab treatment. In previous studies, severe AD [2, 3, 6] , prior history of conjunctivitis [3, 7] , atopic AD phenotype [4, 7] , high baseline IgE levels and eosinophil counts [3] , have been suggested as risk factors for dupilumab-associated conjunctivitis.
The current study reinforces these risk factors for the development of dupilumab-associated conjunctivitis, which has a significant value for the clinical settings. After accounting for any Data are n (%). *Conjunctivitis in which the aetiology remained unspecified. **The incidence was calculated among the 72 patients who were not diagnosed with conjunctivitis at baseline.
